VIVUS, Inc. (NASDAQ:VVUS)

CAPS Rating: 2 out of 5

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.

Results 1 - 20 of 78 : 1 2 3 4 Next »

Recs

0
Member Avatar s2dbaker (93.74) Submitted: 10/16/2013 11:04:44 PM : Outperform Start Price: $9.66 VVUS Score: -101.02

A pill that help prevent type II diabetes and promotes weight loss. This is a winner.

Recs

0
Member Avatar LIFESAVA1 (< 20) Submitted: 4/19/2013 5:31:47 PM : Outperform Start Price: $11.88 VVUS Score: -114.97

VVUS HAS A GREAT WEIGHT LOSS PRODUCT

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:37:23 PM : Underperform Start Price: $10.24 VVUS Score: +116.62

Qsymia was a total flop at initial release, and that is without any competition. As soon as Belviq hits the shelves, Qsymia sales will drop substantially.

Recs

0
Member Avatar SmartEquity (41.36) Submitted: 1/21/2013 9:09:52 AM : Outperform Start Price: $13.34 VVUS Score: -122.41

I believe the scrips will pick up as distribution is improved. The obesity patients will choose a riskier Qsymia over a safer less effective Belviq.

Recs

0
Member Avatar clymerjones (51.97) Submitted: 10/17/2012 11:09:13 AM : Outperform Start Price: $22.25 VVUS Score: -128.20

Strong product/development initiatives will out class the S&P

Recs

0
Member Avatar dausama (86.00) Submitted: 9/23/2012 9:54:13 AM : Underperform Start Price: $20.62 VVUS Score: +128.58

no EU approval

Recs

0
Member Avatar donodonuts (44.67) Submitted: 8/9/2012 7:16:43 AM : Outperform Start Price: $21.77 VVUS Score: -133.56

Sold it at like 8, oops. But their stuff hasn't hit the market yet, I'd like to think it will go up more when they have actual sales.

Recs

0
Member Avatar rick3000 (< 20) Submitted: 7/17/2012 5:16:39 PM : Underperform Start Price: $30.33 VVUS Score: +139.52

Inflated by ARNA approval, will crash to actual value if rejected or with restrictive label. Management has a black eye from handling of FDA announcement.

Recs

0
Member Avatar ravens9111 (60.80) Submitted: 7/16/2012 11:26:58 AM : Underperform Start Price: $27.97 VVUS Score: +139.59

Betting against this stock's FDA decision tomorrow. Price is most likely already priced in for approval. I expect a sell the news event even if approval is granted. However, if rejected, this stock will go to low teens to high single digits.

Recs

0
Member Avatar HIGHG33K (93.14) Submitted: 7/13/2012 8:39:49 PM : Outperform Start Price: $27.55 VVUS Score: -139.74

FDA approval is inevitable.

Recs

0
Member Avatar natemwilson (45.88) Submitted: 6/28/2012 12:08:47 PM : Underperform Start Price: $28.54 VVUS Score: +143.79

Too many adverse side effects to be approved.

Recs

0
Member Avatar nobleartjim (< 20) Submitted: 6/23/2012 9:48:19 AM : Outperform Start Price: $26.34 VVUS Score: -143.24

Recent developing products now undergoing FDA tests appear favorable

Recs

0
Member Avatar BACnumber1 (< 20) Submitted: 6/12/2012 12:13:40 PM : Outperform Start Price: $24.75 VVUS Score: -142.82

Fine stock, but I'm way bigger on ARNA

Recs

0
Member Avatar GoodTrader1 (< 20) Submitted: 6/6/2012 4:38:42 PM : Outperform Start Price: $24.32 VVUS Score: -141.27

high relative strenght

Recs

0
Member Avatar Wanker01 (41.40) Submitted: 5/1/2012 1:07:03 PM : Outperform Start Price: $24.59 VVUS Score: -133.05

Old people want to do it to

Recs

0
Member Avatar donscaccia (< 20) Submitted: 4/26/2012 10:47:24 AM : Outperform Start Price: $24.37 VVUS Score: -135.15

lets go vvus

Recs

0
Member Avatar JacquesHRoy (< 20) Submitted: 4/18/2012 8:32:42 PM : Outperform Start Price: $22.41 VVUS Score: -135.39

Anti-obesity medication is a big MUST in North-America.

Recs

0
Member Avatar henrytsai (36.07) Submitted: 3/31/2012 12:09:34 AM : Outperform Start Price: $23.00 VVUS Score: -133.52

Will obtain FDA approval thus driving price higher.

Recs

0
Member Avatar yandar (< 20) Submitted: 3/24/2012 4:40:03 PM : Outperform Start Price: $22.05 VVUS Score: -133.27

Obesity drug holds too much promise and will get approval despite heart concerns. Warnings appear on labels all the time. Given our societal penchant for eating, this drug could help a large portion of the public. Too many affected individuals to not approve the drug.

Recs

0
Member Avatar kuala1313 (< 20) Submitted: 3/12/2012 5:31:12 PM : Outperform Start Price: $20.69 VVUS Score: -135.24

Anything involving the FDA is a gamble but for the price of admission this is a ride I am willing to take. The downside cost for a ticket is minimal but the upside if approved has the potential to be one of the biggest selling drugs in history...at least until the side effect claims start coming out. If it doesn't get approved in a month it is a 100% loss but if it gets approved the stock will be all over the news and the drug in nearly every home within a year. When that happens the ride is probably over and time to get off before the lawyers start filing claims. Diet pills may not actually work but they certainly sell in the junk food capital of the world.

Results 1 - 20 of 78 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement